Zhang Y, Qian J, Gu C, Yang Y. Alternative splicing and cancer: a systematic review. Signal Transduct Target Ther. 2021 Feb 24;6(1):78. doi: 10.1038/s41392-021-00486-7
Bowling EA, Wang JH, et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021 Jan 21;184(2):384-403.e21. doi: 10.1016/j.cell.2020.12.031
Sherill-Rofe D, Raban O, et al. Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. NAR Cancer. 2022 Apr 8;4(2):zcac013. doi: 10.1093/narcan/zcac013
Quidville V, Alsafadi S, et al. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res. 2013 Apr 1;73(7):2247-58. doi: 10.1158/0008-5472.CAN-12-2501
Karni R, Hippo Y, Lowe SW, Krainer AR. The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15323-7. doi: 10.1073/pnas.0801376105
Blencowe BJ. Splicing regulation: the cell cycle connection. Curr Biol. 2003 Feb 18;13(4):R149-51. doi: 10.1016/s0960-9822(03)00079-4
